Du har precis klickat på en länk som tar dig till en annan webbplats. Om du fortsätter kommer du att lämna denna webbplats och gå till en webbplats som drivs av någon annan.
Medtronic Sverige varken granskar eller kontrollerar innehållet på den andra webbplatsen och tar inget ansvar för eventuella affärstransaktioner som du utför där. Din användning av den andra webbplatsen är föremål för användarvillkoren och sekretesspolicyn på den webbplatsen.
Det är möjligt att vissa produkter på den andra platsen inte är godkända i Sverige.
Den här webbplatsen använder cookies för att lagra information på din dator. Vi använder cookies för att vår webbplats ska fungera och för att ge dig en bättre upplevelse av webbplatsen. Genom att använda webbplatsen godkänner du placeringen av dessa cookies. Du kan när som helst ändra inställningarna för cookies. Läs vår sekretesspolicy för att lära dig mer.
Din webbläsare är inaktuell
Med en uppdaterad webbläsare kommer du att få en bättre upplevelse på Medtronic webbplats. Uppdatera webbläsaren nu.
Välkommen till vår information för hälso- och sjukvårdspersonal.
Här hittar du produktinformation och annan info framtagen för dig som arbetar inom vården.
Arbetar du inom ett vårdyrke?
Following are select findings from feasibility studies performed at three sites in the United States and one site in Europe, demonstrating the probable benefit of ReclaimTM DBS Therapy for OCD* in treating obsessive-compulsive disorder.1
Results are from 26 treatment-resistant OCD patients treated with DBS at 4 collaborating centers. All patients met stringent inclusion criteria, including disease severity (YBOCS > 30), treatment refractoriness, and symptom duration (minimum of 5 years).
Mean age for the patient cohort at time of implant was 37 years, with approximately equal numbers of males and females (53.8% and 46.2%). Mean duration of symptoms for these patients averaged 22 years, demonstrating the long-standing, treatment-resistant nature of the disorder in this population. Treatment duration ranged from 85.6 months to slightly over 3 months for the most recently treated individuals. All patients had been treated with multiple trials of medications and had also undergone cognitive behavioral therapy. Many patients remained on multiple stable medications. A majority of the patients (89%) also reported a history of comorbid depression (major depressive disorder (MDD) associated with their severe OCD.
YBOCS scores were collected over a period of up to 3 years, for the patients treated with DBS at 4 centers. On average, this patient population showed a progressive and sustained improvement in YBOCS ratings, as illustrated in the chart below.
At 12 months, data was available for only 21 of the 26 subjects. At 12 months, the average YBOCS score for the group (n = 21) had decreased 40.7%, with a corresponding decrease of 45.4% for the cohort followed out to 24 months (n = 17). In the subgroup of patients that met clinical response criterion (> 25% or greater reduction on the YBOCS), the magnitude of these improvements was even greater. Using a last observation carried forward (LOCF) analysis for all patients, the average YBOCS reduction was 41.8% at the 12-month time point.
On average, patients treated with DBS at these 4 centers had a greater than two-thirds chance of attaining a meaningful clinical benefit (> 25% YBOCS decrease at last follow-up), and if a patient reached this response criterion, the average improvement at 6 months and 12 months post-treatment was approximately a 50% reduction in YBOCS score.
According to the Expert Consensus Panel on OCD (1997), a responder is considered a subject who demonstrates a 35% reduction in their YBOCS score and a partial responder is a subject with a 25% reduction in their YBOCS score. At 12 months, 10 subjects met the 35% response criterion and an additional 4 met the 25% responder criterion. An LOCF analysis at this time point results in 13 of 26 patients meeting the 35% response level, and 4 patients meeting the 25% level.
At last follow-up, almost two-thirds of the patient population (16/26, 61.5%) met the more conservative criterion for a clinical improvement (> 35% YBOCS reduction), and another 11.5% (3/26) met the 25% reduction response criterion.
These changes in YBOCS scores measured in this patient group reflect a considerable reduction in symptom severity, as defined by this clinical rating scale. At baseline, 100% (26/26) of the patients enrolled into the study protocols at the 4 collaborating centers met the criterion for “severe” OCD (YBOCS score of 30 or greater) as defined by the Expert Consensus Panel on obsessive-compulsive disorder (1997).
A majority of the treatment-resistant patients treated with deep brain stimulation obtained benefit. Approximately two-thirds of the patients met the accepted criterion for a clinical response (25% reduction in YBOCS) at 6 months, 12 months, and last follow-up, and approximately half of the patients met the more stringent criterion of a 35% reduction at these time points. A majority of the patients moved from a severe OCD rating category at baseline, to a mild or moderate rating at subsequent post-treatment time points.
There are 4 subtypes of OCD, according to the Leckman scheme. Subjects with the obsessions and checking subtype had the best response, i.e., 74.0%, as measured by the YBOCS. In addition, the majority of subjects had comorbid anxiety and depression, which also improved during treatment. No subjects with hoarding as their primary subtype were included in the study.2
In conjunction with the YBOCS measures, 3 of the 4 centers also collected corresponding ratings of Global Assessment of Function (GAF), a measure of overall psychological, social, and occupational functioning. At baseline, the majority of patients (20/21) had GAF scores ranging between 20 and 40, indicating very severe disability.
GAF scores improved over time for the vast majority of patients with the average score increasing from a baseline value of 34.8 (n = 21) to 56.1 (n = 20) at 6 months, 56.4 (n = 18) at 12 months, and 59.0 (n = 21) at last follow-up. An LOCF analysis at 12 months shows a similar level of improvement (mean = 57.6) for all 21 patients. This improvement in GAF for the patient population is illustrated in the chart below, which reflects a gradual and sustained increase in this measure of overall function, following deep brain stimulation.
Treating physicians also provided an impression of the overall, global condition of these patients after deep brain stimulation, including psychological, social, functional, occupational, and quality of life considerations. Overall, the treating physicians reported that approximately two-thirds of the patients were much better following deep brain stimulation, compared to their pre-treatment condition.
Four of the 26 patients chose to discontinue stimulation. Three of these four discontinued due to lack of effectiveness. One of these four discontinued because of the inability to achieve an effective level of treatment without adverse events (hypomania). Two of these four elected to have their Reclaim DBS system explanted and proceeded to undergo a capsulotomy. For details on the common adverse events, see the Reclaim DBS Therapy for OCD Clinical Summary.
Reclaim DBS Therapy for OCD Clinical Summary
Leckman JF, Grice DE, Boardman J, Zhang H, Vitale A, Bondi C, Alsobrook J, Peterson BS, Cohen DJ, Rasmussen SA, Goodman WK, McDougle CJ, Pauls DL. Symptoms of obsessive compulsive disorder. Am J Psychiatry. 1997;154:911-917.